Compass Therapeutics (CMPX) investor relations material

Pipeline progress and clinical updates

• Lead bispecific antibody Tavecimab achieved primary endpoint in a randomized trial for biliary tract cancer, showing a 17.1% response rate versus 5.3% for control, with statistical significance.

• Fewer deaths than projected in the Tavecimab study suggest a potential treatment effect, with updated guidance for secondary endpoint data in Q1 2026.

• Investigator-led study at MD Anderson is evaluating Tavecimab in first-line therapy, potentially expanding its use and commercial opportunity.

• Phase II basket study for Tavecimab in DLL4-positive cancers is planned for the first half of next year, targeting multiple tumor types.

• Fast-track status and potential for a U.S. license application in 2026, with possible approval in early 2027.

Innovation in bispecific antibodies

• H371, a PD1-PDL1 bispecific, demonstrated deep responses in refractory non-small cell lung and triple-negative breast cancer patients, with no dose-limiting toxicities in early phase I.

• H371’s novel mechanism converts PD1-positive T cells to functional PD1-negative T cells, representing a next-generation checkpoint inhibitor.

• Expansion cohorts for H371 in lung and breast cancer will begin in Q4, with full dose escalation data expected at a medical meeting later this year.

• 10726, a PD1-VEGF8 bispecific, showed superior preclinical efficacy to Ivernizumab and is set for IND filing in Q4, with clinical entry in 2026.

Manufacturing and operational readiness

• Developed significant bispecific manufacturing expertise, achieving commercial-ready yields of five grams per liter for all three bispecifics.

• BLA-ready manufacturing runs for Tavecimab have been initiated to support potential regulatory filings.

• Manufacturing capability is seen as a key differentiator, surpassing yields of some leading monoclonal antibodies.